Mayne Pharma Group Limited is a specialty pharmaceutical company. The Company is focused on applying its drug delivery to commercialize branded and generic pharmaceuticals. The Company's operating segments are Mayne Pharma International (MPI), US Products (USP) and Metrics Contract Services (MCS). The MPI segment is engaged in manufacture and sale of branded and generic pharmaceutical product and provision of contract manufacturing services to third-party customers within Australia. The USP segment is engaged in the manufacture and distribution of generic and branded pharmaceutical products in the United States. The MCS segment provides contract pharmaceutical development services to third-party customers in the United States. The Company's products include Astrix, Doryx, Eryc, Kadian, Kapanol, Magnoplasm, Lozanoc, SUBA-Itraconazole, ZEBUTAL, ESGIC, ESGIC PLUS, LORCET and LORCET PLUS. The Company also provides contract development and manufacturing services to its clients.
© Data powered by Morningstar, Inc. 2023. All rights reserved.
Neither Morningstar, its affiliates, nor the content providers guarantee the
market indices, commodities and regulatory news headlines, and other data or
content contained herein to be accurate, complete, or timely, and nor shall
they have any liability for its use or distribution. The data contained
herein: (1) is proprietary to Morningstar and/or its affiliates
(collectively, “Morningstar”) and/or their content providers; (2) may not be
copied or distributed; and (3) is not warranted to be accurate, complete, or
timely. Our publications, ratings and products should be viewed as an
additional investment resource, and not as your sole source of information.
Past performance does not necessarily indicate a financial product’s future
performance. To obtain advice tailored to your financial situation, contact
a professional financial adviser. Some material is copyrighted and published
under licence from ASX Operations Pty. Ltd. ACN 004523782.